Literature DB >> 18667021

Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments.

Yutaka Horiguchi1, Eiji Kikuchi, Choichiro Ozu, Toru Nishiyama, Masafumi Oyama, Minoru Horinaga, Kunihiko Yoshioka, Masaaki Tachibana.   

Abstract

Various animal models of bladder tumor have been developed for the preclinical evaluation of therapeutic modalities for the treatment of bladder cancers. The ideal model for the investigation of therapeutic effects of proposed novel intravesical treatments requires the mass of the implanted tumor to be confined to the urothelium of the bladder at least for the initial phase. However, previously reported bladder tumor models are not suitable for the evaluation of intravesical therapies for the treatment of superficial bladder cancer, since the muscle invasive tumors have developed from the beginnings of the experiments. These models are too aggressive to study local treatment effects. In the current study, we demonstrated that careful instillation of MBT-2 mouse bladder cancer cells into the bladder of a syngenic C3H/HeJ mouse could establish a superficial bladder tumor with an incidence of 100%. The procedure and technique for handling animals are simple for standard animal investigators. Maintenance of the in vitro conditions of MBT-2 cells without contamination of Mycoplasma and careful selection of the substrain of C3H mouse seem to be essential for stable tumor establishment. This bladder tumor model appeared to be easy to reproduce among several investigators in different institutions. The orthotopic bladder tumor model, which was confined to urothelium, lets us evaluate various intravesical treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667021     DOI: 10.1111/j.1749-0774.2008.00055.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  21 in total

Review 1.  BCG intravesical instillations: recommendations for side-effects management.

Authors:  P Rischmann; F Desgrandchamps; B Malavaud; D K Chopin
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

2.  Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants.

Authors:  J Chin; S Kadhim; B Garcia; Y S Kim; S Karlik
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

3.  Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.

Authors:  Eiji Kikuchi; Silvia Menendez; Choichiro Ozu; Makoto Ohori; Carlos Cordon-Cardo; Christopher R Logg; Noriyuki Kasahara; Bernard H Bochner
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

4.  Susceptibility of urothelium to neoplastic cellular implantation.

Authors:  T E Weldon; M S Soloway
Journal:  Urology       Date:  1975-06       Impact factor: 2.649

5.  Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model.

Authors:  D I Kleinerman; C P Dinney; W W Zhang; S H Lin; N T Van; J T Hsieh
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

Review 6.  Experimental bladder carcinogenesis-rodent models.

Authors:  P A Oliveira; A Colaco; L F De la Cruz P; C Lopes
Journal:  Exp Oncol       Date:  2006-03

7.  Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin.

Authors:  A Shapiro; D R Kelley; D M Oakley; W J Catalona; T L Ratliff
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

8.  Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines.

Authors:  S Saito; R Bannerji; B Gansbacher; F M Rosenthal; P Romanenko; W D Heston; W R Fair; E Gilboa
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

9.  Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study.

Authors:  E H Ibrahiem; V N Nigam; C A Brailovsky; P Madarnas; M Elhilali
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

10.  Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.

Authors:  Eric B Smith; Michael Schwartz; Hideki Kawamoto; Xueke You; David Hwang; Huixian Liu; Douglas S Scherr
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

View more
  6 in total

1.  Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model.

Authors:  Gaia Codolo; Fabio Munari; Matteo Fassan; Marina de Bernard
Journal:  J Vis Exp       Date:  2015-05-29       Impact factor: 1.355

2.  Potential role of transient receptor potential (TRP) channels in bladder cancer cells.

Authors:  Hideki Mizuno; Yoshiro Suzuki; Masaki Watanabe; Takaaki Sokabe; Tokunori Yamamoto; Ryohei Hattori; Momokazu Gotoh; Makoto Tominaga
Journal:  J Physiol Sci       Date:  2014-05-22       Impact factor: 2.781

3.  Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.

Authors:  Keita Uchino; Fumitaka Takeshita; Ryou-U Takahashi; Nobuyoshi Kosaka; Kae Fujiwara; Haruna Naruoka; Satoru Sonoke; Junichi Yano; Hideo Sasaki; Shiari Nozawa; Miki Yoshiike; Kazuki Kitajima; Tatsuya Chikaraishi; Takahiro Ochiya
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

4.  Experimental rat bladder urothelial cell carcinoma models.

Authors:  Harm C Arentsen; Kees Hendricksen; Egbert Oosterwijk; J Alfred Witjes
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

5.  Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.

Authors:  Koetsu Tamura; Eiji Kikuchi; Tomohiro Konno; Kazuhiko Ishihara; Kazuhiro Matsumoto; Akira Miyajima; Mototsugu Oya
Journal:  BMC Cancer       Date:  2015-04-26       Impact factor: 4.430

6.  Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.

Authors:  Yi Mu; Deyu Sun
Journal:  Med Sci Monit       Date:  2018-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.